Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04246047
Title Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)
Acronym DREAMM 7
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS

Facility Status City State Zip Country Details
GSK Investigational Site Yuma Arizona 85364 United States Details
GSK Investigational Site Denver Colorado 80218 United States Details
GSK Investigational Site Westwood Kansas 66205 United States Details
GSK Investigational Site Cincinnati Ohio 45242 United States Details
GSK Investigational Site Tyler Texas 75702 United States Details
GSK Investigational Site Roanoke Virginia 24014 United States Details
GSK Investigational Site Camperdown New South Wales 2050 Australia Details
GSK Investigational Site Liverpool New South Wales 2170 Australia Details
GSK Investigational Site St Leonards New South Wales 2065 Australia Details
GSK Investigational Site Waratah New South Wales 2298 Australia Details
GSK Investigational Site Wollongong New South Wales 2500 Australia Details
GSK Investigational Site Benowa Queensland 4217 Australia Details
GSK Investigational Site Herston Queensland 4029 Australia Details
GSK Investigational Site Kurralta Park South Australia 5037 Australia Details
GSK Investigational Site Box Hill Victoria 3128 Australia Details
GSK Investigational Site Heidelberg Victoria 3084 Australia Details
GSK Investigational Site Melbourne Victoria 3004 Australia Details
GSK Investigational Site Murdoch Western Australia 6150 Australia Details
GSK Investigational Site Nedlands Western Australia 6009 Australia Details
GSK Investigational Site Brussel 1090 Belgium Details
GSK Investigational Site Bruxelles 1200 Belgium Details
GSK Investigational Site Gent 9000 Belgium Details
GSK Investigational Site Roeselare 8800 Belgium Details
GSK Investigational Site Natal Rio Grande Do Norte 59075-740 Brazil Details
GSK Investigational Site Porto Alegre Rio Grande Do Sul 90035-903 Brazil Details
GSK Investigational Site Florianopolis Santa Catarina 88020-210 Brazil Details
GSK Investigational Site Joinville Santa Catarina 89201-260 Brazil Details
GSK Investigational Site Rio de Janeiro 22775001 Brazil Details
GSK Investigational Site São Paulo 04537-080 Brazil Details
GSK Investigational Site São Paulo 05403-000 Brazil Details
GSK Investigational Site Edmonton Alberta T6G 1Z2 Canada Details
GSK Investigational Site London Ontario N6A 5W9 Canada Details
GSK Investigational Site Québec Ontario G1J 1Z4 Canada Details
GSK Investigational Site Toronto Ontario M4N 3M5 Canada Details
GSK Investigational Site Montréal Quebec H4J 1C5 Canada Details
GSK Investigational Site Guangzhou Guangdong 510060 China Details
GSK Investigational Site Nanjing Jiangsu 210008 China Details
GSK Investigational Site Changchun Jilin 130012 China Details
GSK Investigational Site Jianan Shandong 250012 China Details
GSK Investigational Site Hangzhou Zhejiang 310003 China Details
GSK Investigational Site Beijing 100020 China Details
GSK Investigational Site Beijing 100044 China Details
GSK Investigational Site Beijing 100191 China Details
GSK Investigational Site GuangZhou 510515 China Details
GSK Investigational Site Jiang Su Province 215006 China Details
GSK Investigational Site Shenyang 110001 China Details
GSK Investigational Site Tianjin 300020 China Details
GSK Investigational Site Tianjin 300052 China Details
GSK Investigational Site Wuhan 430022 China Details
GSK Investigational Site Zhengzhou 450052 China Details
GSK Investigational Site Brno 625 00 Czechia Details
GSK Investigational Site Hradec Kralove 500 05 Czechia Details
GSK Investigational Site Ostrava 708 52 Czechia Details
GSK Investigational Site Praha 2 128 08 Czechia Details
GSK Investigational Site Amiens cedex 1 80054 France Details
GSK Investigational Site Caen cedex 9 14033 France Details
GSK Investigational Site Nice 06200 France Details
GSK Investigational Site Paris cedex 13 75651 France Details
GSK Investigational Site Rennes cedex 9 35033 France Details
GSK Investigational Site Ulm Baden-Wuerttemberg 89081 Germany Details
GSK Investigational Site Muenchen Bayern 81377 Germany Details
GSK Investigational Site Wuerzburg Bayern 97080 Germany Details
GSK Investigational Site Duesseldorf Nordrhein-Westfalen 40225 Germany Details
GSK Investigational Site Koeln Nordrhein-Westfalen 50937 Germany Details
GSK Investigational Site Jena Thueringen 07747 Germany Details
GSK Investigational Site Alexandroupolis 68 100 Greece Details
GSK Investigational Site Athens 11528 Greece Details
GSK Investigational Site Thessaloniki 54007 Greece Details
GSK Investigational Site Jerusalem 91120 Israel Details
GSK Investigational Site Kfar Saba 44281 Israel Details
GSK Investigational Site Tel Aviv 64239 Israel Details
GSK Investigational Site Tel Hashomer 52621 Israel Details
GSK Investigational Site Bologna Emilia-Romagna 40138 Italy Details
GSK Investigational Site Meldola Emilia-Romagna 47014 Italy Details
GSK Investigational Site Ravenna Emilia-Romagna 48123 Italy Details
GSK Investigational Site Roma Lazio 00168 Italy Details
GSK Investigational Site Bergamo Lombardia 24127 Italy Details
GSK Investigational Site Brescia Lombardia 25123 Italy Details
GSK Investigational Site Milano Lombardia 20133 Italy Details
GSK Investigational Site Torino Piemonte 10126 Italy Details
GSK Investigational Site Catania Sicilia 95123 Italy Details
GSK Investigational Site Siena Toscana 53100 Italy Details
GSK Investigational Site Aichi 441-8570 Japan Details
GSK Investigational Site Aichi 446-8602 Japan Details
GSK Investigational Site Aichi 467-8602 Japan Details
GSK Investigational Site Aomori 030-8553 Japan Details
GSK Investigational Site Chiba 296-8602 Japan Details
GSK Investigational Site Ehime 790-8524 Japan Details
GSK Investigational Site Fukuoka 806-8501 Japan Details
GSK Investigational Site Fukuoka 807-8555 Japan Details
GSK Investigational Site Fukuoka 810-8563 Japan Details
GSK Investigational Site Fukuoka 815-8555 Japan Details
GSK Investigational Site Fukushima 960-1295 Japan Details
GSK Investigational Site Gifu 503-8502 Japan Details
GSK Investigational Site Gunma 377-0280 Japan Details
GSK Investigational Site Hokkaido 060-8648 Japan Details
GSK Investigational Site Hyogo 670-8540 Japan Details
GSK Investigational Site Kanagawa 221-0855 Japan Details
GSK Investigational Site Kanagawa 247-8533 Japan Details
GSK Investigational Site Kochi 781-8555 Japan Details
GSK Investigational Site Kyoto 602-8566 Japan Details
GSK Investigational Site Nagano 392-8510 Japan Details
GSK Investigational Site Okayama 701-1192 Japan Details
GSK Investigational Site Osaka 530-0012 Japan Details
GSK Investigational Site Osaka 545-8586 Japan Details
GSK Investigational Site Shizuoka 411-8777 Japan Details
GSK Investigational Site Busan 49241 Korea, Republic of Details
GSK Investigational Site Seongnam-si, Gyeonggi-do 13620 Korea, Republic of Details
GSK Investigational Site Seoul 06351 Korea, Republic of Details
GSK Investigational Site Seoul 06591 Korea, Republic of Details
GSK Investigational Site Ulsan 44033 Korea, Republic of Details
GSK Investigational Site Dordrecht 3318 AT Netherlands Details
GSK Investigational Site Groningen 9713 GZ Netherlands Details
GSK Investigational Site Christchurch 8011 New Zealand Details
GSK Investigational Site Dunedin 9054 New Zealand Details
GSK Investigational Site Newtown 6021 New Zealand Details
GSK Investigational Site Takapuna, Auckland 1309 New Zealand Details
GSK Investigational Site Chorzow 41-500 Poland Details
GSK Investigational Site Krakow 30510 Poland Details
GSK Investigational Site Lodz 93-513 Poland Details
GSK Investigational Site Lublin 20-081 Poland Details
GSK Investigational Site Lublin 20-090 Poland Details
GSK Investigational Site Nowy Sacz 33-300 Poland Details
GSK Investigational Site Poznan 60-569 Poland Details
GSK Investigational Site Warszawa 02-781 Poland Details
GSK Investigational Site Moscow 125284 Russian Federation Details
GSK Investigational Site Nizhniy Novgorod 603126 Russian Federation Details
GSK Investigational Site Novosibirsk 630087 Russian Federation Details
GSK Investigational Site Samara 443021 Russian Federation Details
GSK Investigational Site Saratov 410028 Russian Federation Details
GSK Investigational Site St'Petersburg 191024 Russian Federation Details
GSK Investigational Site St. Petersburg 197 089 Russian Federation Details
GSK Investigational Site Ufa 450083 Russian Federation Details
GSK Investigational Site Badalona 08916 Spain Details
GSK Investigational Site Barcelona 08035 Spain Details
GSK Investigational Site Barcelona 08908 Spain Details
GSK Investigational Site Cáceres 10003 Spain Details
GSK Investigational Site Gijón 33394 Spain Details
GSK Investigational Site Madrid 28007 Spain Details
GSK Investigational Site Murcia 30008 Spain Details
GSK Investigational Site Móstoles 28933 Spain Details
GSK Investigational Site Pamplona 31008 Spain Details
GSK Investigational Site Pozuelo De Alarcón/Madrid 28223 Spain Details
GSK Investigational Site Salamanca 37007 Spain Details
GSK Investigational Site Stoke-on-Trent Staffordshire ST4 6QG United Kingdom Details
GSK Investigational Site Sutton Surrey SM2 5PT United Kingdom Details
GSK Investigational Site Bournemouth BH7 7DW United Kingdom Details
GSK Investigational Site Cardiff CF14 4XW United Kingdom Details
GSK Investigational Site Dundee DD1 9SY United Kingdom Details
GSK Investigational Site Leicester LE1 5WW United Kingdom Details
GSK Investigational Site London W12 0NN United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field